New hepa B treatment cited
April 21, 2005 | 12:00am
At the recent 14th biennial conference of the Asian Pacific Association for the Study of the Liver, a new hepatitis B treatment option was cited.
Peginterferon alfa 2-a has been shown to treat both HbeAG-positive and HbeAG-negative chronic hepatitis B, thus removing the need for daily and potentially life-long therapy for the disease.
The studies presented during the conference showed that peginterferon alfa 2-a is superior to lamivudine, the most commonly prescribed medication for hepatitis B.
The new hepa B treatment works in a two-pronged approach: it stimulates the immune system and inhibits virus replication.
Chronic hepatitis B is a major global health problem affecting more than 350 million people. It is one of the causes of liver failure, cirrhosis and liver cancer.
Between one-quarter and one-third of people with chronic hepatitis B will develop progressive liver disease, and an estimated one million will die annually, making the disease the 10th leading cause of death worldwide.
Peginterferon alfa 2-a has been shown to treat both HbeAG-positive and HbeAG-negative chronic hepatitis B, thus removing the need for daily and potentially life-long therapy for the disease.
The studies presented during the conference showed that peginterferon alfa 2-a is superior to lamivudine, the most commonly prescribed medication for hepatitis B.
The new hepa B treatment works in a two-pronged approach: it stimulates the immune system and inhibits virus replication.
Chronic hepatitis B is a major global health problem affecting more than 350 million people. It is one of the causes of liver failure, cirrhosis and liver cancer.
Between one-quarter and one-third of people with chronic hepatitis B will develop progressive liver disease, and an estimated one million will die annually, making the disease the 10th leading cause of death worldwide.
BrandSpace Articles
<
>
- Latest
Latest
Latest
March 3, 2024 - 2:57pm
March 3, 2024 - 2:57pm
February 24, 2024 - 10:30am
By Issam Ahmed | February 24, 2024 - 10:30am
February 8, 2024 - 8:45am
February 8, 2024 - 8:45am
January 29, 2024 - 1:22pm
January 29, 2024 - 1:22pm
January 26, 2024 - 11:13am
By Issam Ahmed | January 26, 2024 - 11:13am
January 25, 2024 - 4:37pm
By Kyoko Hasegawa | January 25, 2024 - 4:37pm
Recommended